M
Myosana Therapeutics
Home | Myosana Therapeutics, Inc.
About Myosana Therapeutics
Myosana Therapeutics is at the forefront of developing a groundbreaking gene therapy platform aimed at treating genetic muscle diseases. Founded in 2018 by Dr. Stan Froehner and Dr. Nick Whitehead, both renowned experts in neuromuscular disease, the company focuses on creating a non-viral, muscle-directed gene therapy. This innovative platform is designed to treat a wide range of neuromuscular disorders and cardiomyopathies, with an initial focus on Duchenne Muscular Dystrophy (DMD), a severe genetic disorder that leads to progressive muscle degeneration and weakness.
The company's business model revolves around research and development, targeting both the pharmaceutical and biotechnology markets. By pioneering a mutation-agnostic approach, Myosana's platform is applicable to patients with any mutation in the DMD gene, potentially transforming the lives of DMD patients and their families. Revenue is generated through partnerships, grants, and future commercialization of their gene therapy solutions.
Myosana Therapeutics serves a specialized client base, including patients suffering from genetic muscle diseases, healthcare providers, and research institutions. The company operates in the highly specialized field of gene therapy, focusing on neuromuscular and cardiac genetic diseases.
Source: Dealroom company dataNews
Open roles
Myosana Therapeutics in the Seattle ecosystem
The Myosana Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed5 investors entered at this stage
Cure Duchenne
Parent Project Muscular Dystrophy
CureDuchenne Ventures
MDA Venture Philanthropy
John Ballantyne
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Myosana Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Myosana Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.


